RESEARCH ARTICLE

Orexin A affects HepG2 human hepatocellular carcinoma cells glucose metabolism via HIF-1α-dependent and -independent mechanism

Xing Wan1*, Yuanyuan Liu2*, Yuyan Zhao2*, Xiaoqi Sun3, Dongxiao Fan3, Lei Guo3*

1 Department of Medical Oncology, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, P.R. China, 2 Department of Endocrinology, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, P.R. China, 3 Department of Orthopedic Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, P.R. China

* These authors contributed equally to this work.

Citation: Wan X, Liu Y, Zhao Y, Sun X, Fan D, Guo L (2017) Orexin A affects HepG2 human hepatocellular carcinoma cells glucose metabolism via HIF-1α-dependent and -independent mechanism. PLoS ONE 12(9): e0184213. https://doi.org/10.1371/journal.pone.0184213

Editor: Pankaj K Singh, University of Nebraska Medical Center, UNITED STATES

Received: March 11, 2017
Accepted: August 21, 2017
Published: September 8, 2017

Copyright: © 2017 Wan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by the National Natural Science Foundation of China (grant numbers 81071460, 81271996).

Competing interests: The authors have declared that no competing interests exist.

Abstract

Orexins are hypothalamic neuropeptides that regulate feeding, reward, wakefulness and energy homeostasis. The present study sought to characterize the involvement of orexin A in glucose metabolism in HepG2 human hepatocellular carcinoma cells, and investigated the role of hypoxia-inducible factor-1α (HIF-1α) in the response. HepG2 cells were exposed to different concentrations of orexin A (10−9 to 10−7 M) in vitro, without or with the orexin receptor 1 (OX1R) inhibitor (SB334867), HIF-1α inhibitor (YC-1) or a combination of both inhibitors. Subsequently, OX1R, HIF-1α expression and localization, glucose uptake, glucose transporter 1 (GLUT1) expression and ATP content were measured. We further investigated the intracellular fate of glucose by measuring the gene expression of pyruvate dehydrogenase kinase 1 (PDK1), lactate dehydrogenase (LDHA) and pyruvate dehydrogenase B (PDHB), as well as metabolite levels including lactate generation and mitochondrial pyruvate dehydrogenase (PDH) activity. The activity of phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway was also assessed. Our results showed that the expression of OX1R was predominantly located in the nucleus in HepG2 cells. Orexin A oxygen-independently promoted the mRNA and protein expression of HIF-1α as well as its nuclear accumulation in HepG2 cells and the elevated HIF-1α protein was associated, at least partly, with the activation of the PI3K/Akt/mTOR pathway. Orexin A stimulated GLUT1 expression, glucose uptake as well as ATP generation in HepG2 cells via OX1R acting through the HIF-1α pathway. Moreover, orexin A inhibited LDHA, PDK1 expression and lactate production, stimulated PDHB expression and PDH enzyme activity independent of HIF-1α. Our results indicated that orexin signaling facilitated the glucose flux into mitochondrial oxidative metabolism rather than glycolysis in HepG2 cells. These findings provide new insight into the regulation of glucose metabolism by orexin A in hepatocellular carcinoma cells.

PLOS ONE | https://doi.org/10.1371/journal.pone.0184213 September 8, 2017 1 / 16
Introduction

Orexin A and orexin B are a pair of hypothalamic neuropeptides that play critical roles in the regulation of feeding, wakefulness, reward system, energy homeostasis as well as other physiological process [1–4]. The actions of orexin peptides are mediated via interaction with two G protein-coupled receptors (GPCRs), orexin receptor types 1 and 2 (OX1R and OX2R, respectively). OX1R has a higher selectivity for orexin A, while OX2R binds both orexin peptides with similar affinity [5]. In addition to hypothalamus, orexins and their receptors are also widely expressed in peripheral tissues, such as adrenal gland, adipose tissue, digestive tract, and gonads [6, 7]. Orexin singling deficiency caused narcolepsy in human and animal models, which was accompanied by metabolic abnormalities, such as elevated incidence of obesity and type 2 diabetes [8, 9]. Recent study demonstrated that transgenic orexin overexpression efficiently protected mice from insulin resistance induced by high fat diet [10], whereas the deletion of orexin caused disarrangement of hepatic insulin signaling and abnormal gluconeogenic activity during ageing [11, 12], suggesting an important role of orexin in glucose metabolism.

Despite the central significance of orexin system in regulating energy and glucose metabolism, little is known about the metabolic effects of orexin on cancer cells. It has been recognized that the metabolic processes of tumor cells are different from that of their normal counterparts. Malignant tumor cells exhibit significantly increased glucose uptake to meet their high energy demands [13]. Moreover, unlike normal differentiated cells, which metabolize glucose preferentially through mitochondrial oxidative phosphorylation for ATP generation, most cancer cells reprogram the metabolic flux towards glycolysis even in the presence of enough oxygen, leading to a state termed “Warburg effect” or “aerobic glycolysis” [14, 15]. This metabolic switch results in anabolic and bioenergetics changes that provide a growth advantage for cancer cells [16, 17], and has been regarded as a critical hallmark of cancer.

Hypoxia-inducible factor-1 (HIF-1), a major transcription factor responsible for cellular adaptation to hypoxia [18], has been implicated in the central regulation of cancer-specific glucose metabolism. HIF-1 is a heterodimer consisting of HIF-1α and HIF-1β. HIF-1β is a constitutively expressed subunit, whereas HIF-1α is an oxygen-sensitive subunit that determines the activity of HIF-1 [19]. Under normoxia, HIF-1α is hydroxylated by proline hydroxylase domain (PHD) proteins, enabling the von Hippel-Lindau (VHL) to recognize and target HIF-1α for ubiquitination and proteasomal degradation [20]. Hypoxia inhibits the activity of PHD and prevents HIF-1α from degradation. HIF-1α thus accumulates and imports into the nucleus, where it forms the heterodimer with HIF-1β, triggering the transcription of diverse genes involved in cell survival, angiogenesis, invasion and cell metabolism [21]. Specifically, the HIF-1 plays a role in regulating intracellular glucose metabolism. By promoting the expression of glucose transporter 1 (GLUT1) and glycolytic enzymes, HIF-1 leads to increased glucose uptake and glycolysis [22]. Moreover, HIF-1 helps to shunt the pyruvate flux into glycolysis rather than tricarboxylic acid (TCA) cycle and oxidative phosphorylation. This is due, at least partly, to the fact that HIF-1 stimulates the expression of lactate dehydrogenase A (LDHA) [21], the enzyme that catalyzes pyruvate to lactate, as well as pyruvate dehydrogenase kinases (PDK) [23, 24], which phosphorylates and inactivates pyruvate dehydrogenase (PDH), the enzyme that processes pyruvate to acetyl-CoA. Certain studies have reported that orexin A can induce the expression of HIF-1α under normoxic conditions [25–27]. However, little is known about the ability of this peptide to regulate HIF-1α in hepatic carcinoma cells.

Recently, the expression of orexin receptors have been detected in a set of tumor cell lines [28–35], signifying a potential role of this peptide in tumor biology. However, the potential role of orexin A and its receptors in hepatic carcinoma cells is unclear. In this study, we sought...
to examine the expression of orexin receptors in HepG2 human hepatocellular carcinoma cells, and further investigated whether the orexin A/OX1R-stimulated HIF-1α signaling mediated its effects on glucose metabolism in HepG2 cells.

**Materials and methods**

**Reagents**

Orexin A was obtained from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum were purchased from Gibco (Grand Island, NY, USA). Cobalt chloride (CoCl₂), Akt inhibitor (LY294002), mTOR inhibitor (tamsirolimus) and HIF-1α inhibitor (YC-1) were purchased from Sigma-Aldrich (St. Louis, MO, USA). OX1R inhibitor (SB334867) was purchased from Tocris Bioscience (Minneapolis, MA, USA). Total/phosphor-Akt polyclonal antibody, total-mTOR polyclonal antibody, phosphor-mTOR monoclonal antibody, GLUT1 monoclonal antibody, OX1R polyclonal antibody, OX2R polyclonal antibody and β-actin polyclonal antibody were all obtained from Abcam (Cambridge, MA, USA). HIF-1α polyclonal antibody was obtained from Novus Biologicals (Littleton, CO, USA).

**Cell culture**

Human hepatocellular carcinoma cell line HepG2 was obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and maintained in DMEM medium supplemented with 10% fetal bovine serum, 50 μg/ml penicillin and 100 μg/ml streptomycin (Xianfeng, Shanghai, China). The cells were grown in a humidified atmosphere containing 5% CO₂ at 37°C. Before the experiment, the cells were grown in petri dishes in a serum-free medium for 24 h. The following day, the cells were treated with different concentrations of orexin A (0, 10⁻⁹, 10⁻⁸ and 10⁻⁷ M). Another group of HepG2 cells was incubated without or with 10⁻⁶ M SB334867 (OX1R inhibitor), 10⁻⁵ M YC-1 (HIF-1α inhibitor), or a combination of both inhibitors prior to stimulation with 10⁻⁷ M orexin A.

**Measurement of glucose uptake**

HepG2 cells were cultured overnight in serum-free DMEM. Cells were rinsed twice with phosphate-buffered saline (PBS) and incubated in glucose-free Krebs–Ringer–HEPES (KRH) buffer (25 mM Hepes, pH 7.4, 1.3 mM CaCl₂, 120 mM NaCl, 1.2 mM MgSO₄, 1.3 mM KH₂PO₄ and 5 mM KCl) with the indicated concentrations of orexin A with or without the OX1R inhibitor, HIF-1α inhibitor, or a combination of both inhibitors. After 30 min, 0.5 μCi of 2-Deoxy-D [³H] glucose (2-DG) (PerkinElmer Life Sciences) was added for 15 min at 37°C. Subsequently, ice-cold PBS was used to terminate the reaction. Cells were solubilized for 10 min in 0.1% sodium dodecyl sulfate (SDS). Aliquots of cell lysates were used for liquid scintillation. Protein concentration was measured using a BCA protein assay reagent kit (Beyotime Institute of Biotechnology, Shanghai, China). Data were normalized to protein concentration and showed as percentage of basal uptake.

**Measurement of cellular ATP**

HepG2 cells were exposed to orexin A at concentrations of 0, 10⁻⁹, 10⁻⁸ and 10⁻⁷ M for 2 h. Another group of cells was incubated without or with the OX1R inhibitor, SB334867 (10⁻⁶ M), HIF-1α inhibitor, YC-1 (10⁻⁵ M), or a combination of both inhibitors for 30 min prior to stimulation with 10⁻⁷ M orexin A for 2 h. ATP content was measured using a ATP Assay kit (Beyotime) according to the manufacturer’s instructions.
Immunofluorescence

HepG2 cells were fixed with 4% paraformaldehyde (Solarbio, Beijing, China) for 30 min, washed with PBS, and permeabilized in 0.1% Triton X-100 (Solarbio) for 30 min. Subsequently, the cells were blocked with 5% bovine serum albumin (BSA, Solarbio) for 30 min at room temperature and then incubated with HIF-1α antibody (1:100, Novus Biologicals) overnight at 4°C. The next day, cells were washed with PBS, incubated with fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG (H+L) secondary antibody (1:100, ZSGB-BIO, Beijing, China) for 30 min at room temperature. Cells were rinsed with PBS, counterstained with 4′, 6-diamidino-2-phenylindole (DAPI) (Solarbio) for 5 min, and visualized with a fluorescence microscope (Olympus).

Measurement of lactate

HepG2 cells were incubated with or without 10⁻⁷ M orexin A for 0, 2, 4 and 8 h in the presence or absence of OX1R inhibitor, SB334867 (10⁻⁶ M) and HIF-1α inhibitor, YC-1 (10⁻⁵ M). Medium from cultured cells was collected and lactate content was measured using a Lactic Acid assay kit (Nanjing Jiancheng Bioengineering Institute, Nan Jing, China) according to the manufacturer’s instructions.

Pyruvate dehydrogenase activity

HepG2 cells were incubated with or without 10⁻⁷ M orexin A for 0, 15, 30, 60 and 120 min in the presence or absence of OX1R inhibitor, SB334867 (10⁻⁶ M) and HIF-1α inhibitor, YC-1 (10⁻⁵ M). Mitochondria was isolated as previously described [36]. PDH activity in mitochondrial lysate was determined by a Pyruvate dehydrogenase(PDH) Enzyme Activity Microplate Assay Kit (Abcam, Cat. no. ab109902) according to the manufacturer’s instructions.

Real-time PCR

Total RNA was extracted from HepG2 cells using TRIsol reagent (Life Technologies Co., Carlsbad, CA, USA). After spectrophotometric quantification, 1 μg total RNA was converted into cDNA using the PrimeScript™ RT reagent kit with gDNA Eraser (Takara Bio, Otsu, Japan) according to the manufacturer’s instructions. Aliquots of cDNA corresponding to equal amounts of RNA were used for the quantification of mRNA by real-time PCR using the Light Cycler 96 real-time quantitative PCR detection system (Roche, Indianapolis, IN, USA). Specific primers were used as follows:HIF-1α forward, 5′-CAA GAA CCT ACT GCT AAT GCC ACC-3′ and reverse, 5′-GTA TGT GGG TAG GAG ATG GAG ATG-3′; PDK1 forward, 5′-CTC AAG TAA TCC TTC CAC CTC AGC-3′ and reverse, 5′-GGA ACA TAC TGA GAC CTC ATC TCC-3′; LDHA forward, 5′-ATC TTG ACC TAC GTG GCT TGG A-3′ and reverse, 5′-CCA TAC AGG CAC ACT GGA ATC TC-3′; PDHB forward, 5′-GTG ATA AAT ATG CGT ACC ATT AGA CC-3′ and reverse, 5′-CAG CAC CAG TGA CAC GAA CAG C-3′. As an internal control for reverse transcription (RT) and reaction efficiency, amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was carried out in parallel for each sample. The specific primers used were: GAPDH forward, 5′-TGA AGG TCG GAG TCA ACG G-3′ and reverse, 5′-CCT GGA AGA TGG TGA TGG G-3′. The reaction system was 25 μl, including 2 μl cDNA template, 2 μl forward and reverse primers, 8.5 μl RNase-free ddH₂O, and 12.5 μl SYBR® Premix Ex Taq™ II (Takara). The PCR reactions were carried out using the following conditions: 95°C for 30 sec, then 40 cycles of 95°C for 5 sec, 60°C for 30 sec, and 95°C for 15 sec. All primers specific to HIF-1α, PDK1, LDHA, PDHB and GAPDH were
Protein preparations and western blot analysis

Total protein was extracted from HepG2 cells using radioimmunoprecipitation assay cell lysis reagent containing proteinase and phosphatase inhibitors (Solarbio). The cells remained in the medium on ice for 30 min with re-dispersion every 5 min. Cell lysates were centrifuged at 12,000 x g for 10 min at 4˚C, and the protein concentrations of the supernatants were determined using the BCA protein assay reagent kit (Beyotime). The supernatants containing total protein were mixed with a corresponding volume of 5X SDS loading buffer and were subsequently denatured by boiling for 10 min. Samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 5% stacking and 12% separating gels. Subsequently, the samples were transferred onto polyvinylidene difluoride (PVDF) membranes (0.2 μm, Immobilon-P; Millipore, Billerica, MA, USA) at 60 V for 2.5 h. After blocking with skimmed dry milk for 2 h at room temperature, the membranes were washed three times with Tris-buffered saline with Tween 20 (TBST) for 30 min. Then they were incubated overnight at 4˚C with the appropriate primary antibody. The primary antibodies and dilutions used were as follows: rabbit anti-human OX1R (cat. no. ab68718, 1:1000), rabbit anti-human OX2R (cat. no. ab129432, 1:500), rabbit anti-human Akt (cat. no. ab8805, 1: 1,000), rabbit anti-human phospho-Akt (cat. no. ab9293, 1: 1,000), rabbit anti-human mTOR (cat. no. ab2732, 1: 2,000), rabbit anti-human phospho-mTOR (cat. no. ab109268, 1: 1,000), rabbit anti-human HIF-1α (cat. no. NB100-479, 1:1000), rabbit anti-human GLUT1 (cat. no. ab115730, 1: 1,000), rabbit anti-human β-actin (cat. no. ab8227, 1: 1,000). The membranes were washed and incubated at room temperature for 1.5 h with the secondary goat anti-rabbit IgG (H+L) antibody (Beyotime, cat. no. A0208, 1: 2,000) conjugated with horseradish peroxidase, then washed three times with TBST for 30 min. The membranes were subjected to enhanced chemiluminescence (ECL) using an ECL detection kit (Beyotime, cat. no. P0018) and quantified using Quantity One software (Bio-Rad Laboratories Inc., Hercules, CA, USA).

Statistical analysis

The results were expressed as means ± standard error of the mean and differences between the means were analyzed by one-way or two-way analysis of variance (ANOVA) where appropriate. \( P < 0.05 \) was considered to be statistically significant. Statistical analysis was performed using the SPSS 15.0 software package (SPSS Inc., Chicago, IL, USA).

Results

OX1R expression and localization in HepG2 cells

We first performed western blot to assess the protein expression of orexin receptors in HepG2 cells. The expression of OX1R was detected in HepG2 cells. Moreover, orexin A stimulation for 24 h resulted in a dose-dependent increase in OX1R expression, with the highest response, 3.02-fold compared to the control, observed at \( 10^{-7} \) M (Fig 1A). These effects were blocked with \( 10^{-6} \) M SB334867, a specific OX1R inhibitor (Fig 1A). We did not detect the expression of OX2R in HepG2 cells.

Next, we investigated the cellular distribution of OX1R protein in HepG2 cells by immunofluorescent staining. The OX1R-immunopositivity was predominantly located in the nucleus. OX1R was also present in cytoplasm and plasma membrane. Incubation of the cells with orexin A for 24 h resulted in a clear increase in overall OX1R labeling (Fig 1B). These results...
indicated that OX1R was expressed in HepG2 hepatoma cells and exhibited to be highly sensitive to exogenous orexin A stimulation.

**Orexin A-mediated induction of HIF-1α**

Given the role of HIF-1α in glucose metabolism and cancer progression, we investigated several levels of HIF-1α regulation in HepG2 cells stimulated with orexin A. Real-time PCR assays demonstrated that the mRNA level of HIF-1α was dose-dependently increased in response to orexin A treatment. The effects of $10^{-9}$ M and $10^{-7}$ M orexin A were statistically significant, increasing HIF-1α mRNA expression by 3.38- and 4.95-fold compared with the control, respectively (Fig 2A). As regards protein expression, a basal level of HIF-1α was seen in normoxic HepG2 cells. Incubation of the cells with orexin A under normoxia resulted in time- and dose-dependent induction of HIF-1α (Fig 2B and 2C). Treatment with $10^{-7}$ M orexin A for 2 h exerted the most potent effect, increasing HIF-1α protein expression by 3.02-fold over basal. Moreover, pretreatment with the OX1R inhibitor SB334867 ($10^{-6}$ M) and HIF-1α inhibitor YC-1 ($10^{-5}$ M) for 30 min effectively reduced the elevated HIF-1α protein stimulated by orexin A (Fig 2C).

We next performed immunofluorescence analysis to investigate the intracellular localization of HIF-1α in HepG2 cells upon orexin A stimulation. As shown in Fig 2D, HIF-1α could be weakly detected in HepG2 cells in normoxia, while a distinct increase of nuclear staining of HIF-1α was observed in cells treated with CoCl$_2$ (stimulating hypoxia). Exposure of the cells with orexin A under normoxia also induced HIF-1α protein to accumulate in the nucleus. Collectively, these results indicated that orexin A promoted the mRNA and protein expression of HIF-1α as well as its nuclear accumulation in HepG2 cells under normoxia.

**PI3K/Akt/mTOR signaling pathway is involved in orexin A-mediated induction of HIF-1α**

It has been demonstrated that HIF-1α could be regulated at translational level via PI3K/Akt/mTOR pathway under normoxia [37, 38]. We thus evaluated the role of PI3K/Akt/mTOR in
Orexin A-induced HIF-1α protein accumulation in HepG2 cells. The data showed that stimulation of the cells with orexin A increased the phosphorylation of Akt and mTOR in HepG2 cells, while the total amount of Akt and mTOR were not altered (Fig 3A and 3B, respectively). Blocking OX1R with SB334867 (10^{-6} M) prior to orexin A treatment markedly reversed these effects, suggesting that orexin A induced activation of PI3K/Akt/mTOR pathway in HepG2 cells via OX1R. Moreover, administration of the LY294002 (10^{-5} M, Akt inhibitor), temsirolimus (10^{-5} M, mTOR inhibitor), or a combination of both inhibitors not only suppressed Akt/mTOR (Fig 3A and 3B, respectively), but also abrogated the elevated HIF-1α protein induced by orexin A (Fig 3C). These results indicated that the PI3K/Akt/mTOR pathway participated in orexin A-mediated HIF-1α protein accumulation in HepG2 cells.

Orexin A stimulates GLUT1 expression and glucose uptake in HepG2 cells

GLUT1 is a major contributor to glucose uptake and plays a critical role in malignant glucose metabolism. We next investigated the effects of orexin A on GLUT1 protein expression and
the associated glucose uptake in HepG2 cells. Western blot showed a concentration-dependent increase in GLUT1 expression in HepG2 cells treated with orexin A. The maximal stimulation was induced by $10^{-7} \text{M}$ orexin A, enhancing GLUT1 expression by 2.43-fold compared with untreated cells (Fig 4A). Orexin A also stimulated glucose uptake in HepG2 cells. Stimulation with $10^{-8} \text{M}$ and $10^{-7} \text{M}$ orexin A induced a 1.46- and 1.71-fold increase in glucose uptake, respectively compared with the control (Fig 4B). To characterize the role of HIF-1$\alpha$ in this process, YC-1 was exploited to suppress HIF-1$\alpha$ pathway. Pretreatment with the HIF-1$\alpha$ inhibitor YC-1 ($10^{-5} \text{M}$), OX1R inhibitor SB334867 ($10^{-6} \text{M}$), or the combination of both inhibitors effectively blocked orexin A-mediated up-regulation of GLUT1 protein expression and glucose uptake in HepG2 cells (Fig 4A and 4B, respectively). These data suggested that orexin A, acting at OX1R, stimulated glucose uptake and GLUT1 expression in HepG2 cells via HIF-1$\alpha$.

**Fig 3.** Effects of PI3K/Akt/mTOR signaling on orexin A-induced HIF-1$\alpha$ protein accumulation. HepG2 cells were treated with or without $10^{-7} \text{M}$ orexin A for 30 min in the presence or absence of $10^{-5} \text{M}$ LY294002 (Akt inhibitor) or $10^{-5} \text{M}$ temsirolimus (mTOR inhibitor), $10^{-6} \text{M}$ SB334867 (OX1R inhibitor), as well as the combination of both inhibitors. The phosphorylation of Akt (A) and mTOR (B) was normalized against the total protein expression. The total protein expression was used as an internal control for equal protein loading. Protein activation was measured by western blot. (C) Cells were treated with or without $10^{-7} \text{M}$ orexin A for 2 h in the presence or absence of $10^{-5} \text{M}$ LY294002 (Akt inhibitor), $10^{-5} \text{M}$ temsirolimus (mTOR inhibitor), or the combination of both inhibitors. HIF-1$\alpha$ protein expression was measured by western blot. Data are presented as mean ± standard error of the mean based on experimental analysis in triplicate. *$P<0.05$ compared to control.

https://doi.org/10.1371/journal.pone.0184213.g003

**Fig 4.** Effects of orexin A on GLUT1 protein expression and glucose uptake in HepG2 cells. Cells were treated with the indicated doses of orexin A with or without the OX1R inhibitor SB334867 ($10^{-6} \text{M}$), HIF-1$\alpha$ inhibitor, YC-1 ($10^{-5} \text{M}$), or a combination of both inhibitors. (A) After 2 h, GLUT1 protein expression were determined by western blot. (B) After 30 min, glucose uptake was also measured. Data are presented as mean ± standard error of the mean based on experimental analysis in triplicate. *$P<0.05$ compared to control.

https://doi.org/10.1371/journal.pone.0184213.g004
Effects of orexin A on cellular ATP levels in HepG2 cells

To determine whether the increased glucose uptake into cells induced by orexin A resulted in elevated energy production, we investigated the effects of orexin A on cellular ATP levels in HepG2 cells. A dose-dependent increase in ATP content was observed after 2 h of orexin A stimulation. Concentrations of $10^{-8}$ and $10^{-7}$ M orexin A led to a 2.06- and 3.03-fold increase in ATP content, respectively compared with the control. However, these effects were abrogated in the presence of the HIF-1α inhibitor YC-1 ($10^{-5}$ M), OX1R inhibitor SB334867 ($10^{-6}$ M), or a combination of both inhibitors (Fig 5). These findings suggested that HIF-1α participated in orexin A-induced stimulation of ATP production in HepG2 cells.

Orexin A facilitates the metabolic flux towards TCA cycle rather than glycolysis in HepG2 cells

Glucose is first metabolized to pyruvate through glycolysis in the cytosol. The fate of pyruvate represents a key metabolic branchpoint, as it can be converted to lactate by LDHA, thus facilitating glycolysis, or can be catalyzed to acetyl-CoA by PDH for entry into the TCA cycle in mitochondria. Pyruvate dehydrogenase kinase 1 (PDK1) phosphorylates PDH and inhibits its activity. We further investigated the intracellular fate of glucose by measuring the changes in LDHA, PDK1 and PDHB (a subunit of PDH complex) expression in HepG2 cells upon orexin A treatment. As seen in Fig 6A, orexin A stimulation resulted in a 0.50- and 0.53-fold reduction in LDHA and PDK1 mRNA levels, respectively compared with the control. In contrast, the expression of PDHB was significantly increased. Blocking OX1R with SB334867 ($10^{-6}$ M) prior to orexin A administration significantly dampened these responses. The HIF-1α inhibitor YC-1 ($10^{-5}$ M), however, did not abolish orexin A-induced above effects. It is noteworthy
that the expression of LDHA and PDK1 were further inhibited by YC-1 in orexin A-treated HepG2 cells (Fig 6A).

We further explored whether the changes observed in the transcription data resulted in the corresponding alterations in metabolite levels. Conditioned media was collected following orexin A exposure for the indicated times and assayed for lactate production. As expected, a dramatic orexin A-induced drop in lactate production was seen at all of the time points indicated. These effects were abolished by the OX1R inhibitor SB334867 (10^{-6} M). However, pharmacological blockade of HIF-1α using YC-1 did not prevent orexin A from suppressing lactate production (Fig 6B).

The activity of PDH, a key regulatory enzyme converting glucose flux into mitochondria, was next determined in orexin A-treated HepG2 cells. We observed in accordance with our gene expression analyses that orexin A significantly increased PDH activity at all of the time points indicated. The observed increase in PDH activity was blunted when orexin A was combined with OX1R inhibitor SB334867 (10^{-6} M). However, inhibition of HIF-1α did not reverse this increase in PDH activity (Fig 6C). Together, measurements of LDHA, PDHB, PDK1 expression, lactate production and mitochondrial PDH enzyme activity indicated that orexin signaling appeared to facilitate the metabolic flux towards TCA cycle and away from glycolysis independent of HIF-1α in HepG2 cells.

Discussion
In this study, we demonstrated the presence and cellular distribution of OX1R in HepG2 hepatocellular carcinoma cells. Orexin A promoted the expression and nuclear accumulation of HIF-1α in HepG2 cells under normoxia and the enhanced HIF-1α protein was associated with the activation of PI3K/Akt/mTOR signaling pathway. Orexin A-mediated induction of HIF-1α resulted in increased GLUT1 expression, glucose uptake as well as ATP generation in HepG2 cells. Moreover, orexin signaling directed the glucose flux towards TCA cycle rather than glycolysis. The HIF-1α pathway, although clearly responsive to orexin A, did not play an important role in mediating this metabolic branchpoint.

Orexin peptides are endogenous ligands for two receptors, OX1R and OX2R. The two receptors show broad and distinct distribution throughout the brain and peripheral tissues [7]. Many physiological actions regulated by orexins derive from highly diversified cellular responses to the orexin receptors stimulation. Recently, a growing body of evidence has

Fig 6. Effects of orexin A on PDHB, LDHA, PDK1 mRNA expression, lactate generation and PDH enzyme activity in HepG2 cells. Cells were treated with or without 10^{-7} M orexin A for the indicated times in the presence or absence of the OX1R inhibitor SB334867 (10^{-6} M) and HIF-1α inhibitor, YC-1 (10^{-6} M). (A) After 2 h, PDHB, LDHA, PDK1 mRNA expression were determined by real-time PCR. (B) Lactate generation was measured using a Lactic Acid assay kit. (C) PDH enzyme activity was determined using a Pyruvate dehydrogenase (PDH) Enzyme Activity Microplate Assay Kit. Data are presented as mean ± standard error of the mean based on experimental analysis in triplicate. * P<0.05, ** P<0.01 compared to control.

https://doi.org/10.1371/journal.pone.0184213.g006
demonstrated the existence of orexin receptors in cancer cells [28–35], such as human colon carcinoma cells [28], gallbladder cancer cells [33] and so on, suggesting a potential relevance of this peptide in cancer biology. Orexins and their receptors have been well-documented for their role in regulating growth and apoptosis of these cancer cells. However, the expression and metabolic function of orexin receptors in hepatoma cells remains largely unknown. In the present study, we identified the presence of OX1R in HepG2 hepatocellular carcinoma cells. Consistent with a previous study by Kishida et al [30], we did not detect the expression of OX2R in HepG2 cells. We further investigated the cellular distribution of OX1R in HepG2 cells and found that OX1R immunoreactivity was predominantly located in the nucleus. Expression of OX1R was also detected in the cytoplasm and plasma membrane. Orexin A treatment of the HepG2 cells increased the protein expression of OX1R and overall OX1R labeling. Moreover, SB334867, a specific OX1R inhibitor, effectively blocked orexin A-mediated metabolic effects in HepG2 cells, suggesting that the actions of orexin A in HepG2 cells were mediated via a direct interaction with OX1R.

Previous studies using orexin-knockout mice have demonstrated the involvement of orexin signaling in glucose metabolism [11]. Orexin deficiency in mice caused impaired glucose tolerance and insulin resistance associated with aging [11]. An in vitro study performed in 3T3-L1 adipocytes and isolated primary rat adipocytes demonstrated that orexin A facilitated GLUT4 translocation and stimulated glucose uptake [39]. Shen et al. reported that orexin A stimulated GLUT4 mRNA expression in differentiated 3T3-L1 adipocytes [40]. In addition, orexin A and its receptor acting at ventromedial hypothalamic nucleus, promoted2-deoxy-D-glucose (2DG) uptake and glycogen synthesis in skeletal muscle [41]. GLUT1 is the major contributor to the transport and metabolism of glucose in cancer cells, including HepG2 hepatic carcinoma cells [42, 43]. In the present study, orexin A significantly stimulated GLUT1 protein expression and glucose uptake in HepG2 cells. Moreover, the increased glucose utilization resulted in elevated cellular energy production as suggested by increased ATP content upon orexin A stimulation. Orexin A-mediated up-regulation of cellular energy metabolism seemed to be consistent with the involvement of orexin signaling in the promotion of energy expenditure and obesity resistance [44].

We further investigated the intracellular fate of glucose set off by orexin A. Pyruvate, as the end product of glycolysis, represents a key control point in cellular glucose metabolism. LDHA catalyzes pyruvate to lactate in the cytosol, whereas PDH processes pyruvate to acetyl-CoA for use in the TCA cycle and oxidative phosphorylation in mitochondria. PDK1 phosphorylates PDH and suppresses its activity, thus limiting influx of pyruvate into the TCA cycle. Our results showed that orexin A treatment of HepG2 cells resulted in a stimulation of PDHB expression and down-regulation of both LDHA and PDK1. It seems that orexin A signaling facilitated the glucose flux through TCA cycle and away from glycolysis. Coincide with the transcription data, orexin A stimulation resulted in a clear reduction in lactate production and significant elevation of PDH enzyme activity in HepG2 cells. These data were in line with the results of a previous study demonstrating the role of orexin in promoting the metabolic flux into mitochondrial glucose oxidation [25].

Accumulating studies show that activation of OX1R/OX2R by orexin A influences some molecules involved in intracellular metabolic function. HIF-1α, a key mediator of hypoxia response, has been revealed to play critical roles in tumor metabolism [45]. HIF-1α protein concentrations are low under normoxia as a consequence of ubiquitination and proteasome degradation by VHL [20]. During hypoxia, HIF-1α escapes from this degradation. Recent studies demonstrated that orexin A could induce HIF-1α expression via down-regulation of VHL under normoxic conditions [25, 26]. Butterick et al. suggested that orexin A-mediated
regulation of energy expenditure and obesity resistance depended in part on signaling pathways involving HIF-1α [44]. In the present study, we also demonstrated that orexin A could induce HIF-1α under normoxic conditions. Our results showed that orexin A stimulated HIF-1α mRNA and protein expression as well as its nuclear accumulation in HepG2 cells. In addition to oxygen-dependent regulation, HIF-1α can also be regulated at translational level via PI3K/Akt/mTOR pathway under normoxia [37, 38]. Recent reports demonstrated that orexin A could activate the PI3K/Akt/mTOR pathway in many types of cells [39, 46, 47]. Moreover, activation of PI3K/Akt cascades was reported to induce HIF-1α protein accumulation in HepG2 cells [48]. Consistent with these findings, our data showed that orexin A induced Akt and mTOR phosphorylation in HepG2 cells, which participated in orexin A-induced up-regulation of HIF-1α. These findings indicated that orexin A-mediated induction of HIF-1α in HepG2 cells was due to both elevated HIF-1α transcript levels and an activation of PI3K/Akt/mTOR pathway, which promoted the protein expression of HIF-1α. More studies are necessary to elucidate the molecular mechanism underlying orexin A-mediated induction of HIF-1α transcription and localization.

We further investigated the relevance of HIF-1α in orexin A-mediated metabolic effects in HepG2 cells. Orexin A increased GLUT1 expression, glucose uptake as well as ATP production in HepG2 cells. However, these effects were significantly blocked by the HIF-1α inhibitor YC-1, suggesting an important role of HIF-1α in glucose metabolism. These results were in line with the general function of HIF-1α in promoting glucose uptake and glycolytic activity in cancer cells [45]. Furthermore, it is well-established that HIF-1 helps to favor the intracellular glucose flux through glycolysis, which is dependent mainly on its effects in stimulating the expression of both LDHA and PDK1 [23, 49]. It can be deduced that orexin A-mediated induction of HIF-1α may result in an increase in LDHA and PDK1 expression, facilitating the pyruvate flux into glycolysis. However, measurements of both gene expression and metabolic output indicated that this was not the case in HepG2 cells treated with orexin A. Moreover, pharmacological blockade of HIF-1α did not abolish orexin A-mediated effects on LDHA, PDK1, PDHB expression, lactate content as well as PDH enzyme activity. Specially, we found an additional reduction in LDHA and PDK1 expression following YC-1 treatment in orexin A-stimulated HepG2 cells. Based on these findings, we can hypothesize that HIF-1α does have a role in stimulating LDHA and PDK1 expression, whereas in orexin A-treated HepG2 cells, there may be some other mechanisms that override HIF-1α-mediated preference for directing pyruvate flux into glycolysis. Further studied are necessary to clarify the exact molecular mechanisms behind these events. Besides HIF-1α, several regulatory pathways are also known to be involved in the regulation of glucose metabolism in tumor cells, such as Myc, PI3K/Akt/mTOR and AMP-activated protein kinase (AMPK) [17, 50]. Whether these signal molecules play a role in orexin A-mediated effects on glucose metabolism in hepatocellular carcinoma cells remains to be determined.

In conclusion, we demonstrated that orexin A oxygen-independently promoted the mRNA and protein expression of HIF-1α as well as its nuclear accumulation in HepG2 cells and the elevated HIF-1α protein was associated, at least partly, with the activation of PI3K/Akt/mTOR pathway. HIF-1α was involved in orexin A-stimulated increase in GLUT1 expression, glucose uptake as well as ATP generation. Moreover, orexin A facilitated the glucose flux into mitochondria oxidative metabolism independent of HIF-1α. Our understanding of the effects of orexin signaling on glucose metabolism in hepatocellular carcinoma remains at an early stage, further studies such as in vivo experiments are necessary to clarify this novel field. Anyway, our findings add a new dimension to the metabolic activities of this neuropeptide on hepatocellular carcinoma cells.
Supporting information

S1 Fig. The time course effects of orexin A on OX1R expression in HepG2 human hepatocellular carcinoma cells. HepG2 cells were treated with $10^{-7}$ M orexin A for the indicated times. OX1R protein expression was determined by western blot analysis. Data are presented as mean ± standard error of the mean based on analysis in triplicate. *P* < 0.05 compared to control. (TIF)

S2 Fig. Effects of YC-1 on LDHA, PDK1 and PDHB mRNA expression in HepG2 cells. Cells were treated with or without $10^{-5}$ M HIF-1α inhibitor YC-1 for 2 h, LDHA, PDK1 and PDHB mRNA expression were determined by real-time PCR. Data are presented as mean ± standard error of the mean based on analysis in triplicate. *P* < 0.05 compared to control. (TIF)

S3 Fig. Effects of YC-1 on lactate content and PDH enzyme activity in HepG2 cells. (A) Cells were treated with or without $10^{-5}$ M HIF-1α inhibitor YC-1 for 8 h, lactate generation was measured using a Lactic Acid assay kit. (B) Cells were treated with or without $10^{-5}$ M HIF-1α inhibitor YC-1 for 2 h, PDH enzyme activity was determined using a Pyruvate dehydrogenase (PDH) Enzyme Activity Microplate Assay Kit. Data are presented as mean ± standard error of the mean based on experimental analysis in triplicate. *P* < 0.05 compared to control. (TIF)

Acknowledgments

We are thankful to China medical university affiliated hospital laboratory center for kindly providing equipments needed. We thank Ms. Liang Zhang for excellent technical assistance. This work was supported by the National Natural Science Foundation of China (grant numbers 81071460 and 81271996).

Author Contributions

Conceptualization: Xing Wan, Lei Guo.

Data curation: Yuanyuan Liu, Xiaoqi Sun, Dongxiao Fan.

Funding acquisition: Dongxiao Fan.

Investigation: Dongxiao Fan.

Project administration: Yuyan Zhao.

Resources: Lei Guo.

Supervision: Xiaoqi Sun.

Writing – original draft: Xing Wan, Yuyan Zhao, Lei Guo.

Writing – review & editing: Yuanyuan Liu, Lei Guo.

References

1. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998; 92: 573–585. PMID: 9491997
2. Kodadek T, Cai D. Chemistry and biology of orexin signaling. Mol Biosyst. 2010; 6: 1366–1375. https://doi.org/10.1039/c003468a PMID: 2053299

3. Xu TR, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cell Signal. 2013; 25: 2413–2423. https://doi.org/10.1016/j.cellsig.2013.07.025 PMID: 23917208

4. Li J, Hu Z, Lecca L. The hypocretins/orexins: integrators of multiple physiological functions. Br J Pharmacol. 2014; 171: 332–350. https://doi.org/10.1111/bjhp.12415 PMID: 24102345

5. Karteris E, Randeva HS. Orexin receptors and G-protein coupling: evidence for another ‘promiscuous’ seven transmembrane domain receptor. J Pharmacol Sci. 2003; 93: 126–128. PMID: 14501163

6. Nakabayashi M, Suzuki T, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, et al. Orexin-A expression in human peripheral tissues. Mol Cell Endocrinol. 2003; 205: 43–50. PMID: 12890566

7. Leonard CS, Kukkonen JP. Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol. 2014; 171: 294–313. https://doi.org/10.1111/bjhp.12296 PMID: 23840855

8. Schuld A, Hebebrand J, Geller F, Pollmachi T. Increased body-mass index in patients with narcolepsy. Lancet. 2000; 355: 1274–1275.

9. Hara J, Beuckmann CT, Nambu K, Chenelli RM, Sinton CM, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001; 30: 345–354. PMID: 11394998

10. Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T, et al. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab. 2009; 9: 64–76. https://doi.org/10.1016/j.cmet.2008.10.010 PMID: 19117547

11. Tsuneki H, Murata S, Anzawa Y, Soeda Y, Tokai E, Wada T, et al. Age-related insulin resistance in hypothalamus and peripheral tissues of orexin knockout mice. Diabetologia. 2006; 51: 657–667. https://doi.org/10.1007/s00412-006-0929-8 PMID: 16298906

12. Tsuneki H, Tokai E, Nakamura Y, Takahashi K, Fujita M, Asaoka T, et al. Hypothalamic orexin prevents hepatic insulin resistance via daily bidirectional regulation of autonomic nervous system in mice. Diabetologia. 2014; 67: 459–470. https://doi.org/10.2337/db13-0695 PMID: 25249578

13. DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008; 18: 54–61. https://doi.org/10.1016/j.gde.2008.02.003 PMID: 18387799

14. Warburg O. On the origin of cancer cells. Science. 1956; 123: 309–314. PMID: 13298683

15. Zhang Y, Yang JM. Altered energy metabolism in cancer: A unique opportunity for therapeutic intervention. Cancer Biol Ther. 2013; 14: 81–89. https://doi.org/10.1016/j.cbt.22998 PMID: 23192270

16. Vander Heiden MG, Canto LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029–1033. https://doi.org/10.1126/science.1160809 PMID: 19460998

17. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7: 11–20. https://doi.org/10.1016/j.cmet.2007.10.002 PMID: 18177721

18. Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun. 2005; 338: 627–638. https://doi.org/10.1016/j.bbrc.2005.08.165 PMID: 16153922

19. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004; 5: 343–354. https://doi.org/10.1038/nrm1366 PMID: 15122348

20. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008; 30: 393–402. https://doi.org/10.1016/j.molcel.2008.04.009 PMID: 18498744

21. Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enhance tumour regression. Nature. 2006; 441: 437–443. https://doi.org/10.1038/nature04871 PMID: 16724055

22. Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, et al. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol. 2001; 21: 3436–3444.

23. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006; 3: 187–197. https://doi.org/10.1016/j.cmet.2006.01.012 PMID: 16517406

24. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006; 3: 177–185. https://doi.org/10.1016/j.cmet.2006.02.002 PMID: 16517405

25. Sikder D, Kodadek T. The neurohormone orexin stimulates hypoxia-induciblefactor-1 activity. Genes Dev. 2007; 21: 2995–3005. https://doi.org/10.1101/gad.1584307 PMID: 18006690
Yuan LB, Dong HL, Zhang HP, Zhao RN, Gong G, Chen XM, et al. Neuroprotective effect of orexin-A is mediated by an increase of hypoxia-inducible factor-1 activity in rat. Anesthesiology. 2011; 114: 340–354. https://doi.org/10.1097/ALN.0b013e318206ff6f PMID: 2139965

27. Feng Y, Liu T, Li XQ, Liu Y, Zhu XY, Jankovic J, et al. Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson’s disease. Neurosci Lett. 2014; 579: 35–40. https://doi.org/10.1016/j.neulet.2014.07.014 PMID: 25038418

28. Voisin T, El Firar A, Fasseu M, Rouyer-Fessard C, Descautoire V, Walker F, et al. aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis. Cancer Res. 2011; 71: 3341–3351. https://doi.org/10.1158/0008-5472.CAN-10-3473 PMID: 21415167

29. Rouet-Benzenbe P, Rouyer-Fessard C, Jarry A, Avondo V, Pouzet C, Yanagisawa M, et al. Orexins acting at native OX1 receptor in colon cancer and neuroblastoma cells or at recombinant OX1 receptor suppress cell growth by inducing apoptosis. J Biol Chem. 2004; 279: 45875–45886. https://doi.org/10.1074/jbc.M401362000 PMID: 15310763

30. Alexandre D, Hautot C, Melhio M, Jeandel L, Courel M, Voisin T, et al. The orexin type 1 receptor is over-expressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis. Eur J Cancer. 2014; 50: 2126–2133. https://doi.org/10.1016/j.ejca.2014.05.008 PMID: 24914018

31. Liu Y, Zhao Y, Ju S, Guo L. Orexin A upregulates the protein expression of OX1R and enhances the proliferation of SGC-7901 gastric cancer cells through the ERK signaling pathway. Int J Mol Med. 2015; 35: 539–545. https://doi.org/10.3892/ijmm.2014.2038 PMID: 25515760

32. Voisin T, El Firar A, Avondo V, Laburthe M. Orexin-induced apoptosis: the key role of the seven-transmembrane domain orexin type 2 receptor. Endocrinology. 2006; 147: 4977–4984. https://doi.org/10.1210/en.2006-0201 PMID: 16857748

33. Kishida M, Ishige K, Horibe T, Tada N, Koibuchi N, Shoda J, et al. Orexin 2 receptor as a potential target for immunotoxin and antibody-drug conjugate cancer therapy. Oncol Lett. 2012; 3: 525–529. https://doi.org/10.3892/ol.2011.526 PMID: 22740944

34. Biegarska K, Sokolowska P, Jöhrn O, Zawilska JB. Orexin A suppresses the growth of rat C6 glioma cells via a caspase-dependent mechanism. J Mol Neurosci. 2012; 48: 706–712. https://doi.org/10.1007/s12031-012-9799-0 PMID: 22588980

35. Spinazzi R, Rucinski M, Neri G, Malendowicz LK, Nussdorfer GG. Preproorexin and orexin receptors are expressed in cortisol-secreting adrenocortical adenomas, and orexins stimulate in vitro cortisol secretion and growth of tumor cells. J Clin Endocrinol Metab. 2005; 90: 3544–3549. https://doi.org/10.1210/jc.2004-2385 PMID: 15797953

36. Prabh A, Sarcar B, Kahali S, Yuan Z, Johnson JJ, Adam KP, et al. Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth. Cancer Res. 2014; 74: 787–796. https://doi.org/10.1158/0008-5472.CAN-13-1423 PMID: 24351290

37. Agani F, Jiang BH. Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets. 2013; 13: 245–251. PMID: 23297826

38. Lee BL, Kim WH, Jung J, Cho SJ, Park JW, Kim J, et al. Hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer. Carcinogenesis. 2008; 29: 44–51. https://doi.org/10.1093/carcin/gbm232 PMID: 17984117

39. Skrzeszyski M, Le TT, Kaczmarek P, Pruszynska-Oszmalek E, Pietrzak P, Szczepankiewicz D, et al. Orexin A stimulates glucose uptake, lipid accumulation and adiponectin secretion from 3T3-L1 adipocytes and isolated primary rat adipocytes. Diabetes. 2011; 54: 1841–1852. https://doi.org/10.1007/s12558-011-1252-2 PMID: 21505958

40. Shen Y, Zhao Y, Zheng D, Chang X, Ju S, Guo L. Effects of orexin A on GLUT4 expression and lipid content via MAPK signaling in 3T3-L1 adipocytes. J Steroid Biochem Mol Biol. 2013; 38: 376–383.

41. Shiuchi T, Haque M S, Okamoto S, Inoue T, Kageyama H, Lee S, et al. Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab. 2009; 10: 466–480. https://doi.org/10.1016/j.cmet.2009.09.013 PMID: 19945404

42. Takanaga H, Chaudhuri B, Frommer WB. GLUT1 and GLUT9 as major contributors to glucose influx in HepG2 cells identified by a high sensitivity intramolecular FRET glucose sensor. Biochim Biophys Acta. 2008; 1778: 1091–1099. https://doi.org/10.1016/j.bbamem.2007.11.015 PMID: 18177733

43. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol. 2009; 174: 1544–1552. https://doi.org/10.2353/ajpath.2009.080596 PMID: 19285567

44. Butterick TA, Billington CJ, Kotz CM, Nixon JP. Orexin: pathways to obesity resistance? Rev Endocr Metab Disord. 2013; 14: 357–364. https://doi.org/10.1007/s1154-013-9259-3 PMID: 24005942

45. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol. 2009; 19: 12–16. https://doi.org/10.1016/j.semcancer.2008.11.009 PMID: 19114105
46. Sokołowska P, Urbańska A, Biegańska K, Wagner W, Ciszewski W, Namiecińska M, et al. Orexins protect neuronal cell cultures against hypoxic stress: an involvement of Akt signaling. J Mol Neurosci. 2014; 52: 48–55. https://doi.org/10.1007/s12031-013-0165-7 PMID: 24243084

47. Ju SJ, Zhao Y, Chang X, Guo L. Orexin A protects cells from apoptosis by regulating FoxO1 and mTORC1 through the OX1R/PI3K/AKT signaling pathway in hepatocytes. Int J Mol Med. 2014; 34: 153–159. https://doi.org/10.3892/ijmm.2014.1769 PMID: 24807827

48. Han X, Sun S, Zhao M, Cheng X, Chen G, Lin S, et al. Celastrol stimulates hypoxia-inducible factor-1 activity in tumor cells by initiating the ROS/Akt/p70S6K signaling pathway and enhancing hypoxia-inducible factor-1α protein synthesis. PLoS One. 2014; 9: e112470. https://doi.org/10.1371/journal.pone.0112470 PMID: 25383959

49. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010; 20: 51–56. https://doi.org/10.1016/j.gde.2009.10.009 PMID: 19942427

50. Obre E, Rossignol R. Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. Int J Biochem Cell Biol. 2015; 59: 167–181. https://doi.org/10.1016/j.biocel.2014.12.008 PMID: 25542180